Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to shrink stomach tumors in Mid-Stage trial

NCT ID NCT06628310

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025

Summary

This Phase 2 study tests a new drug, telisotuzumab adizutecan (ABBV-400), combined with standard chemotherapy and an immunotherapy drug for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will receive either the new combo or standard treatment to see which works better at slowing cancer growth. The study will also find the best dose of the new drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AdventHealth Orlando /ID# 268561

    RECRUITING

    Orlando, Florida, 32803, United States

  • Aichi Cancer Center /ID# 268124

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Algemeen Ziekenhuis klina /ID# 268754

    RECRUITING

    Brasschaat, Antwerpen, 2930, Belgium

  • Barts Health NHS Trust /ID# 270796

    RECRUITING

    London, Greater London, E1 2ES, United Kingdom

  • Beijing Cancer Hospital /ID# 268455

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • CHU de Liege /ID# 270223

    RECRUITING

    Liège, 4000, Belgium

  • Cancer Hospital Chinese Academy of Medical Sciences(Langfang) /ID# 277479

    RECRUITING

    Langfang, Hebei, 065000, China

  • Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 268763

    RECRUITING

    Montreal, Quebec, H2X 0C1, Canada

  • China Medical University Hospital /ID# 267667

    RECRUITING

    Taichung, 40447, Taiwan

  • City Of Hope - Atlanta. /ID# 280646

    RECRUITING

    Newnan, Georgia, 30265, United States

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 272630

    RECRUITING

    Irvine, California, 92618, United States

  • City of Hope National Medical Center /ID# 268690

    RECRUITING

    Duarte, California, 91010, United States

  • Complexo Hospitalario Universitario de Ourense /ID# 270042

    RECRUITING

    Ourense, 32005, Spain

  • Duke University Medical Center /ID# 268186

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Hadassah Medical Center-Hebrew University /ID# 267753

    RECRUITING

    Jerusalem, 91120, Israel

  • Haematologisch-Onkologische Praxis Eppendorf /ID# 268024

    RECRUITING

    Hamburg, 20249, Germany

  • Harbin Medical University Cancer Hospital /ID# 268452

    RECRUITING

    Harbin, Heilongjiang, 150081, China

  • Hattiesburg Clinic /ID# 268572

    RECRUITING

    Hattiesburg, Mississippi, 39401, United States

  • Hospital Clinico Universitario de Valencia /ID# 270040

    RECRUITING

    Valencia, 46010, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 270037

    RECRUITING

    Madrid, 28007, Spain

  • Hospital Universitario de Navarra /ID# 270119

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Jewish General Hospital /ID# 268413

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267672

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Krankenhaus Nordwest /ID# 268462

    RECRUITING

    Frankfurt am Main, Hesse, 60488, Germany

  • Linkou Chang Gung Memorial Hospital /ID# 267668

    RECRUITING

    Taoyuan City, 333, Taiwan

  • Meir Medical Center /ID# 267998

    RECRUITING

    Kfar Saba, Central District, 4428164, Israel

  • Millennium Research & Clinical Development /ID# 268540

    RECRUITING

    Houston, Texas, 77090, United States

  • NHS Tayside Health Board /ID# 270799

    RECRUITING

    Dundee, DD2 1SG, United Kingdom

  • National Cancer Center Hospital /ID# 268648

    RECRUITING

    Chuo-Ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 268083

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital /ID# 267669

    RECRUITING

    Tainan, 704, Taiwan

  • National Taiwan University Hospital /ID# 267666

    RECRUITING

    Taipei, 100, Taiwan

  • Oxford University Hospital NHS Trust /ID# 274614

    RECRUITING

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

  • Pan American Center for Oncology Trials /ID# 268833

    RECRUITING

    Rio Piedras, 00935, Puerto Rico

  • Princess Margaret Cancer Centre /ID# 268277

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Queen Elizabeth Hospital Birmingham /ID# 271199

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

  • Shaare Zedek Medical Center /ID# 267752

    RECRUITING

    Jerusalem, 9103102, Israel

  • Shizuoka Cancer Center /ID# 268123

    RECRUITING

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Soroka Medical Center /ID# 268301

    RECRUITING

    Beersheba, Southern District, 8410101, Israel

  • TUM Klinikum rechts der Isar /ID# 267792

    RECRUITING

    Munich, Bavaria, 81675, Germany

  • Taipei Veterans General Hospital /ID# 267664

    RECRUITING

    Taipei, 112, Taiwan

  • Tel Aviv Sourasky Medical Center /ID# 267755

    RECRUITING

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Cancer Institute Hospital Of JFCR /ID# 268656

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

  • The first Affiliated Hospital, Zhejiang University School of Medicine. /ID# 268782

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • UCLA - Santa Monica /ID# 270024

    RECRUITING

    Santa Monica, California, 90404, United States

  • Union Hospital - Tongji Medical College /ID# 268796

    RECRUITING

    Wuhan, Hubei, 430022, China

  • Universitaetsklinikum Freiburg /ID# 270407

    RECRUITING

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Universitaetsklinikum Leipzig /ID# 270432

    RECRUITING

    Leipzig, Saxony, 04103, Germany

  • Universitair Ziekenhuis Leuven /ID# 269957

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Telisotuzumab adizutecan (ABBV-400) combined with budigalimab, fluorouracil, and leucovorin

What this could lead to

If successful, this could offer a new first-line treatment option for people with advanced stomach or esophageal cancer, potentially improving how long they live without their cancer growing.

What could go wrong

This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. The new drug combination may cause side effects or not work better than current treatments.

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC ADENOCARCINOMA